Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Offers affordable, high-quality solutions for diabetes care
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Branded formulation business continues to perform well across domestic and export markets
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated